Rich is a co-founder and Partner of Longwood Fund. He has co-founded and helped to build several successful biotech companies including Concert Pharmaceuticals (NASDAQ: CNCE), where he serves as Chairman, Sirtris Pharmaceuticals (NASDAQ: SIRT acquired by GSK in 2008), and Longwood portfolio companies Alnara Pharmaceuticals (acquired by Lilly in 2010), Verastem (NASDAQ: VSTM), OvaScience (NASDAQ: OVAS), where he serves as Chairman and FlexPharma (NASDAQ FLKS). Rich also serves as a Director of Longwood portfolio companies Mitobridge, Inc. and Colorescience, Inc.
Prior to co-founding Longwood, he was General Partner of RA Capital, a biotechnology investment fund he co-founded in 2001. Mr Aldrich was also a founding employee of Vertex Pharmaceuticals (NASDAQ: VRTX) where he held the position of Senior VP and Chief Business Officer and managed all commercial and operating functions from 1989 to 2001. Prior to joining Vertex, Rich held several management positions at Biogen, Inc.
Rich serves on the Board of the Massachusetts Eye & Ear Infirmary. He received his undergraduate degree from Boston College, and an MBA from the Amos Tuck School at Dartmouth College.
Dr. Cha has served as a member of KalVista’s board of directors since the consummation of the Carbylan transaction in 2016. Dr. Cha served as a member of the Carbylan board of directors starting in 2007. In 2000, Dr. Cha joined Vivo Capital, a healthcare investment firm, where he has served in various positions, most recently as a managing partner. Dr. Cha currently serves as a member of the boards of Aclaris Therapeutics, Ascendis Pharma A/S, AirXpanders and several private companies.
Dr. Cha received a B.S. and an M.S. from Stanford University and an M.D. and a Ph.D. from the University of California at Los Angeles.
Andrew is a co-founder of KalVista Pharmaceuticals and its CEO. Prior to KalVista, Andrew held various senior management positions including chief executive, vice president of business development and director or clinical and regulatory affairs in biotech and specialty pharmaceutical companies in the United States and United Kingdom. During his career he has identified, negotiated and executed strategic corporate transactions on a global basis, including merger and acquisitions, national and international product licences, IP and technology licences, and R&D alliances.
Andrew received a BA from the University of Utah, and MBA from The Wharton School, University of Pennsylvania, with a major in Finance.
Dr. Oronsky has served as a member of KalVista’s board of directors since the consummation of the Carbylan transaction in 2016. Dr. Oronsky has been a full-time member of InterWest’s healthcare team since 1994, where he currently serves as a Senior Partner. In addition to being a Senior Partner at InterWest, Dr. Oronsky also serves as a Senior Lecturer in the Department of Medicine at Johns Hopkins Medical School. He is a member of the board of directors of Applied Genetic Technologies Corporation, Dynavax Technologies, TESARO and a number of private pharmaceutical companies. Dr. Oronsky was formerly Vice President for Discovery Research for the Lederle Laboratories division of American Cyanamid Company where he directed all of the research for new drugs and supervised approximately three hundred employees. Dr. Oronsky holds a Ph.D. in Immunology from Columbia University and has published over 125 scientific articles.
Dr. Joshua Resnick is a highly-regarded life sciences leader, entrepreneur, and investment professional with more than 15 years of experience in investing, company formation, and company leadership across all stages from discovery through commercialization. Before joining SVLS, Dr. Resnick was President and Managing Partner at MRL Ventures Fund, the early-stage therapeutics-focused corporate venture fund that he established, built and managed within Merck & Co. Prior to MRL Ventures, Dr. Resnick was a Venture Partner with Atlas Venture, focusing on company formation, seed and Series A investing. During his tenure at Atlas, Dr. Resnick was also the Founder and CEO of two start-ups in the immuno-oncology and neuro spaces. Prior to Atlas Venture, Dr. Resnick was a Partner at Prism Venture Partners, where he focused on early-stage biopharmaceutical, medical device, tools and diagnostics investments. Dr. Resnick is also an Attending Physician at Massachusetts General Hospital as well as Brigham and Women’s Hospital, and an Instructor in Medicine at Harvard Medical School.
Dr. Resnick graduated Magna Cum Laude from Williams College and received his MD and MBA from the University of Pennsylvania School of Medicine and Wharton School of Business.
Rajeev is a Managing Director and Portfolio Manager at RA Capital Management. He is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools. Rajeev is active in the firm’s outreach efforts, speaking frequently both at industry events and in classrooms.
Prior to joining RA Capital, he worked as a Senior Project Leader at Altus Pharmaceuticals, a spin-off company of Vertex Pharmaceuticals. At Altus, he assessed business processes and implemented system solutions for all science areas.
Rajeev graduated from Cornell University, where he majored in Chemistry with a concentration in Economics. He is an active member of the Big Brothers of Massachusetts Bay program.
Edward W. Unkart has served as a member of KalVista’s board of directors since the consummation of the Carbylan transaction in 2016. Mr. Unkart joined the Carbylan board of directors in 2014. Previously, Mr. Unkart served as a member of the board of directors of XTENT and VNUS Medical Technologies. Prior to that, Mr. Unkart served as vice president of finance and administration and chief financial officer of SurgRx, a manufacturer of medical devices. Mr. Unkart currently serves on the board of directors of a privately-held medical device company.
Mr. Unkart is a Certified Public Accountant and received a B.S. and an M.B.A. from Stanford University.